# B-Lymphocyte Immunotherapy in Islet Transplantation

> **NCT00468442** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 2 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **BIOLOGICAL:** Allogeneic Pancreatic Islet Cells
- **BIOLOGICAL:** Antithymocyte globulin
- **BIOLOGICAL:** Daclizumab
- **BIOLOGICAL:** Rituximab
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00468442
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2016-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468442, "B-Lymphocyte Immunotherapy in Islet Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00468442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*